Schering Aktiengesellschaft

Bayer Schering Pharma Ag

Schering Aktiengesellchaft

Schering Aktiensgesellschaft

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Thomas Backensfeld

Ralph Lipp

Wolfgang Heil

Johannes Wilhelm Tack

Susanne Keitel

Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and &#x3b2;-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.

Compositions of estrogen-cyclodextrin complexes

Cyclodextrin-drospirenone inclusion complexes

Described are inclusion complexes formed between cyclodextrin and drospirenone. In a specific embodiment of the invention, the cyclodextrin is &bgr;-cyclodextrin. The invention further relates to methods of providing such an inclusion complex, and to the use of said inclusion complex for improving the solubility of drospirenone, for providing pharmaceutical compositions, for use as a medicament in the treatment of symptoms associated with menopause and in female contraception.

Low-dosed steroid tablets that contain gallic acid ester as an

Solid dosage forms that contain clathrates of 17.alpha.-ethinyl estradiol

Growing community of inventors

Berlin, Germany

Thomas Backensfeld